Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances
|発行||Insight Pharma Reports||商品コード||199300|
|次世代シーケンシングによる勢い：市場は技術と技術革新に反応 Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances|
|出版日: 2011年06月07日||ページ情報: 英文||
This report focuses on current and innovative NGS technologies, services and markets to answer such questions as;
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances describes these innovations and analyzes their impact on this extremely dynamic technology and market sector.
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances updates the product offerings from Roche/454, Illumina, Life Technologies (Ion Torrent), Complete Genomics (CGI), Helicos, Pacific Biosciences (PacBio). As well as NGS upstream sample preparation and downstream informatics, aspects of NGS that have developed into substantial and fast-growing markets of their own. Companies in the informatics space covered in this report include Geospiza, Accelrys, GenoLogics, CLC bio, GenomeQuest, Partek, and DNAStar and Ingenuity Systems.
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances looks at a number of new product and technology candidates in varying stages of development. As the report highlights, some candidates are mainly extensions of current technologies, while others represent something very different.
Large companies have entered the new technology race such as General Electric, IBM as well as Life Technologies with its Starlight system. Many small entrepreneurial companies are also covered in this report including GnuBio' s with its microreactors, Halcyon Molecular and ZS Genetics' use of scanning transmission electron microscopy, Intelligent Bio-Systems' 40 million five micron wells, NABsys, using a hybridization-assisted nanopore method, NobleGen' s approach involving preliminary replacement of each base by longer oligonucleotides prior to sequencing and LightSpeed Genomics where patents suggest involving novel optical scanning methodology.
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances investigates the market dynamics where Illumina, Life Technologies, and Roche currently dominate a sequencer market now estimated to exceed $1 billion per year. It' s a market where companies are making continual advances in cost and performance at a pace exceeding that associated with semiconductor technology, where market adoption, application diversity, and implications for life science research continue to advance.
Ken Rubenstein, PhD, a biochemist and molecular biologist, received his PhD at the University of Wisconsin and postdoctoral training at the University Of Pennsylvania School Of Medicine. He was a key innovator and research manager for Syva Company, the diagnostics branch of Syntex Corporation. During his 13 years with Syva, Dr. Rubenstein became vice president, scientific affairs, and a function that included strategic planning. Since 1983, he has served as a technology and marketing consultant to biomedical companies and an industry analyst, with more than 40 published studies to his credit.
This chapter deals with new sequencing technologies and systems still in research or under development. Some can reasonably be considered extensions of second-generation technologies, but others represent a potential great leap forward in performance and cost-effectiveness. For the most part, methods in the second category face significant conceptual and practical difficulties, and have not yet crossed the commercial feasibility barrier. After considering companies active in this area, we review some notable academic research, some of it done in collaboration with corporate partners.